Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy.
about
Metabonomic window into hepatitis B virus-related hepatic diseasesNuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applicationsAn introduction to molecular imaging in radiation oncology: a report by the AAPM Working Group on Molecular Imaging in Radiation Oncology (WGMIR)Multiparametric MR Imaging in Abdominal Malignancies.Parametric exploration of the liver by magnetic resonance methodsMRS-based Metabolomics in Cancer Research.Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease.NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of H and P MRS applications.Multiple breath-hold proton spectroscopy of human liver at 3T: Relaxation times and concentrations of glycogen, choline, and lipids.Fully navigated 3 T proton magnetic resonance spectroscopy of liver metastases with inner-volume saturation.Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumorsHepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers.Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics.Hepatocellular carcinoma: diagnostics and screening.Hepatocellular nodules in liver cirrhosis: MR evaluation.Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.Application of Single Voxel 1H Magnetic Resonance Spectroscopy in Hepatic Benign and Malignant Lesions.In vivo magnetic resonance spectroscopy of liver tumors and metastases.Combining nuclear magnetic resonance spectroscopy and mass spectrometry in biomarker discovery.
P2860
Q26771253-F497AD38-6BBD-4A4F-9413-FBCDB9370F5DQ26772297-C19396C6-9307-4FD7-87CE-FB95BCCCBB04Q27002845-88D90046-89BF-4937-A84E-0F7D77AE8E56Q30364605-660345D9-71A6-4C2D-8CA8-6D229C3718B2Q30485888-4320250C-1289-4176-8CAB-B4798C1F5127Q30842175-3D629FC0-8977-42CB-B9CC-263DD93394C0Q33866965-B884375F-1CDD-44DD-A559-2B763CDEF85BQ35079419-C41E1F92-F3B4-4D94-BA6A-654E16D8A687Q36075759-2E35FCCC-60F5-4109-968A-3EBD7672B556Q36350022-1AFE0A93-086E-4B49-9B12-6438ECECA419Q36376197-50DBCF8D-16B6-4B42-9631-D615208021DFQ37196041-F3807A78-E816-40C9-86EE-7CEBE988161CQ37578500-61396DC6-9211-486F-BE30-32ABA1100A19Q37734427-8E75CE78-A31E-4FBD-9C96-B554883C425FQ37801938-D198553A-0C17-435F-BE18-DD8AC8E12729Q37813192-CD6157CF-3D2B-4A4B-B300-CB4A932C5ECBQ37852598-E8065721-94DF-4FC4-B55D-5A79321416CBQ38172834-8FEE7C83-8269-42C8-BCAB-29F1A275C40CQ40268874-B29173DD-66EF-4B4B-A085-31C5D445187BQ43027090-6CFAE3E1-63B1-4F23-91A2-C88F5D1F12D1Q45022635-F6F601C8-FCEF-495E-9458-E47EB8453987
P2860
Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pathology of hepatocellular ca ...... tical classification strategy.
@en
type
label
Pathology of hepatocellular ca ...... tical classification strategy.
@en
prefLabel
Pathology of hepatocellular ca ...... tical classification strategy.
@en
P2093
P1433
P1476
Pathology of hepatocellular ca ...... tical classification strategy.
@en
P2093
Brion Dolenko
Carolyn E Mountford
Cynthia L Lean
Dorothy Painter
Peter Russell
Ray L Somorjai
Robyne Soper
P304
P356
10.1080/0031302021000009324
P577
2002-10-01T00:00:00Z